HighVista Strategies LLC Buys Shares of 31,886 Urogen Pharma $URGN

HighVista Strategies LLC purchased a new position in Urogen Pharma (NASDAQ:URGN) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 31,886 shares of the company’s stock, valued at approximately $636,000. HighVista Strategies LLC owned approximately 0.07% of Urogen Pharma at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. State of Wyoming purchased a new stake in shares of Urogen Pharma during the 3rd quarter valued at $66,000. Russell Investments Group Ltd. grew its position in Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after acquiring an additional 3,125 shares in the last quarter. Osaic Holdings Inc. increased its stake in Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after acquiring an additional 3,070 shares during the last quarter. Strs Ohio bought a new position in Urogen Pharma in the third quarter valued at $76,000. Finally, CWM LLC raised its position in Urogen Pharma by 18.0% during the third quarter. CWM LLC now owns 4,271 shares of the company’s stock valued at $85,000 after purchasing an additional 650 shares in the last quarter. Institutional investors own 91.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on URGN. D. Boral Capital reaffirmed a “buy” rating and set a $33.00 price target on shares of Urogen Pharma in a research note on Monday, March 2nd. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a research report on Monday, March 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Urogen Pharma currently has a consensus rating of “Moderate Buy” and an average target price of $33.29.

Insider Activity

In related news, General Counsel Jason Drew Smith sold 7,479 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51. Following the transaction, the general counsel directly owned 51,326 shares in the company, valued at $1,010,608.94. This trade represents a 12.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark Schoenberg sold 7,373 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $145,174.37. Following the transaction, the insider owned 144,985 shares in the company, valued at approximately $2,854,754.65. The trade was a 4.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.70% of the stock is currently owned by insiders.

Urogen Pharma Stock Performance

URGN stock opened at $18.73 on Tuesday. The firm has a market cap of $911.78 million, a P/E ratio of -5.85 and a beta of 1.34. The firm’s fifty day moving average is $20.41 and its 200 day moving average is $20.88. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $30.00.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.12. The business had revenue of $37.84 million during the quarter, compared to the consensus estimate of $39.92 million. As a group, analysts forecast that Urogen Pharma will post -3.12 EPS for the current year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.